1 Glorious Growth Stock Down 68% to Buy Hand Over Fist, According to Wall Street

Workiva reported Q1 revenue of $247 million, up 20% year over year and ahead of the $245 million forecast, while GAAP profit improved to $18.9 million from a $21.3 million loss a year ago. Management raised 2026 revenue guidance slightly to $1.039 billion, and higher-spending customer cohorts grew 38% to 605 customers at $300,000+ ACV and 39% to 265 customers at $500,000+ ACV. The stock has fallen 39% this year and 68% from its 2021 high, but analysts remain bullish with an average price target of $84.55, implying 71% upside.

Analysis

WK’s setup is less about “AI proof” and more about whether a mission-critical workflow tool can keep compounding ACV while the market is pricing it like a slow-growth seat-license vendor. The key second-order positive is that compliance/reporting software is one of the few enterprise categories where AI can actually increase vendor dependence: more automation means more generated content, more auditability requirements, and a higher need for structured controls around model output. That supports stickiness rather than displacement, especially if management keeps monetizing AI as an add-on to a value-based contract base.

The most important signal is not broad customer count, but the acceleration in the highest-spending cohorts and NRR above 110%. That implies the growth engine is increasingly coming from workflow expansion inside existing accounts, which is the piece least vulnerable to macro scrutiny and easiest to underwrite over 12-24 months. If this continues for another couple of quarters, consensus will likely need to re-rate WK from a “decaying SaaS multiple” to a cash-generative compliance platform with mid-teens top-line durability.

The bearish overhang is execution, not product relevance. If AI features remain incremental rather than workflow-defining, the stock can stay cheap for longer because investors will treat the valuation reset as deserved. The near-term catalyst path is straightforward: two consecutive quarters of >10% NRR and sustained mid-20s growth in large ACV cohorts could force estimate raises and multiple expansion; the risk case is a pause in expansion spending, which would quickly expose how much of the thesis depends on upsell momentum rather than new logo growth.

Key Decisions for Investors

• Go long WK on weakness with a 3-6 month horizon; thesis is multiple re-rating if large-ACV cohort growth and NRR stay above current levels. Best risk/reward is entering only below the current forward sales discount versus its own history, because downside is mostly valuation compression while upside comes from estimate revisions.
• Use a call spread in WK (6-12 months out) to express upside from a re-rating without paying full delta; structure around a move toward the analyst consensus range, with breakeven requiring only a partial normalization of the P/S multiple.
• Pair long WK / short a higher-multiple, seat-based SaaS name with weaker retention and more AI-disruption exposure. The relative-value trade should work if the market continues to punish “generic SaaS” while rewarding companies with workflow-critical, value-based pricing.
• Avoid chasing the move after a guidance beat; wait for any post-earnings consolidation. The stock likely needs proof of continued large-customer expansion before the market will pay up, so the cleaner entry is on a 10-15% pullback or after the next report confirms trend persistence.
• Monitor for a reversal trigger: if NRR slips below 108% or large-ACV growth decelerates for two quarters, cut the long. That would signal the valuation floor may still be too high relative to growth durability.